Novel therapies in the management of type I diabetes mellitus

Panminerva Medica

Volumn 54, Issue 4, 2012, Pages 257-270

  Ludvigsson, J ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Antibodies, monoclonal; Autoantigens; C peptide; Diabetes mellitus, type 1; Probiotics; Vaccines, dna

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; INSULIN; PROBIOTIC AGENT;

ARTICLE; ATTITUDE TO HEALTH; BLOOD; BLOOD GLUCOSE MONITORING; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; METABOLISM; METHODOLOGY; MOTIVATION; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME; VACCINATION;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOTHERAPY; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN-SECRETING CELLS; MOTIVATION; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; PROBIOTICS; RISK FACTORS; TREATMENT OUTCOME; VACCINATION;

EID: 84871545051     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Aanstoot H.J., Anderson B.J., Daneman D., Danne T., Donaghue K., Kaufman F., Réa R.R., Uchigata Y. The global burden of youth diabetes: Perspectives and potential. Pediatr Diabetes 2007; 8( Suppl 8): 1-44.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
3. Bojestig M., Arnqvist H.J., Hermansson G., Karlberg B.E., Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994;330:15-8. (Pubitemid 24018611)
4. Wild D, Von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns 2007;68:10-5. (Pubitemid 47126791)
5. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359: 1464-76.
6. Choudhary P, Shin J, Wang Y, Evans ML, Hammond PJ, Kerr D, Shaw JA, Pickup JC, Amiel SA. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: Reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011; 34: 2023-2025.
7. Danne T, Kordonouri O, Holder M, Haberland H, Golembowski S, Remus K, Blasig S, Wadien T, Zierow S, Hartmann R, Thomas A. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther 2011; 13: 1-6
8. Hovorka R. Closed-loop insulin delivery: From bench to clinical practice. Nat Rev Endocrinol 2011; 7: 385-95.
9. Hovorka R, Allen JM, Ellen D, Chassin LJ, Harris J, Xing D et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: A phase 2 randomised crossover trial. Lancet 2010; 375: 743-751
10. Madsbad S, Alberti KG, Binder C, Burrin JM, Faber OK, Krarup T, Regeur L. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J 1979; 2: 1257-9.
11. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003; 26: 832-6.
12. Wahren J, Ekberg K, Jörnvall H. C-peptide is a bioactive peptide. Diabetologia 2007;50:503-9. (Pubitemid 46215490)
13. Jun HS. Regeneration of pancreatic beta cells. Front Biosci 2008 May l; 13: 6170-82.
14. Gonez LJ, Knight KR. Cell therapy for diabetes: Stem cells, progenitors or beta-cell replication? Mol Cell Endocrinol 2010; 323: 5561.
15. Ludvigsson J. C-peptide an adequate endpoint in type 1 diabetes. Diabetes Metab Res Rev 2009; 25: 691-3.
16. Virtanen SM, Bärlund S, Salonen M, Savilahti E, Reunanen A, Paronen J et al. Feasibility and compliance in a nutritional primary prevention trial in infants at increased risk for type 1 diabetes. Acta Paediatr 2011; 100: 557-64
17. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974: 2: 1279-82.
18. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983;222:1337-9. (Pubitemid 14204704)
19. Baekkeskov S. Immunoreactivity to a 64,000 Mr human islet cell antigen in sera from insulin-dependent diabetes mellitus patients and individuals with abnormal glucose tolerance. Mol Biol Med 1986; 3: 137-42
20. Savola K, Bonifacio E, Sabbah E, Kulmala P, Vähäsalo P, Karjalainen J et al. IA-2 antibodies - a sensitive marker of IDDM with clinical onset in childhood and adolescence. Diabetologia 1998;41:424-9. (Pubitemid 28157413)
21. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007;104:17040-5. (Pubitemid 350210987)
22. Ludvigsson J, Heding L, Lieden G, Marner B, Lernmark A. Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J (Clin Res Ed) 1983;286:176-8. (Pubitemid 13147594)
23. Dupre J, Stiller CR, Gent M, Donner A, von Graffenried B, Heinrichs D et al. Clinical Trials of Cyclosporin in IDDM. Diabetes Care 1988;Suppl 1:37-44. (Pubitemid 19005575)
24. Eisenbarth GS, Srikanta S, Jackson R, Rabinowe S, Dolinar R, Aoki T et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Research 1985;2:271-6 (Pubitemid 16213226)
25. Chase HP, Butler-Simon N, Garg S, McDuffie M, Hoops SL, O'Brien D. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990;33:444-6 (Pubitemid 20220946)
26. Pozzilli P, Visalli N, Signore A, Baroni MG, Buzzetti R, Cavallo MG et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia 1995; 38: 848-52.
27. Coutant R, Landais P, Rosilio M, Johnsen C, Lahlou N, Chatelain P et al. Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia 1998;41:1040-6. (Pubitemid 28394409)
28. Ludvigsson J, Samuelsson U, Johansson C, Stenhammar L. Treatment with antioxidants at onset of type 1 diabetes in children: a randomized, double-blind placebo-controlled study. Diabetes Metab Res Rev 2001; 17:131-6. (Pubitemid 32427961)
29. Ludvigsson J, Samuelsson U, Ernerudh J, Johansson C, Stenhammar L, Berlin G. Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. Arch Dis Child 2001;85:149-54. (Pubitemid 32701684)
30. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D et al. A single course of anti-CD3 monoclonal antibody hOKT3gammal (Ala-Ala) results in improvement in Cpeptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-9. (Pubitemid 40770766)
31. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-608.
32. Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010; 53: 614-23.
33. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R et al. Type 1 diabetes trialnet anti-CD20 study group rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361: 2143-52.
34. Gottlieb et al. Abstract Annual Meeting of ADA, 2011.
35. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378: 487-97
36. Gundersen E. Is diabetes of infectious origin? J Infectious Dis 1927; 41: 197-202.
37. Hiltunen M, Lönnrot M, Hyöty H. Immunisation and type 1 diabetes mellitus: is there a link? Drug Saf 1999;20:207-12. (Pubitemid 29134895)
38. Lindberg B, Ahlfors K, Carlsson A, Ericsson UB, Landin-Olsson M, Lernmark A et al. Previous exposure to measles, mumps, and rubella-but not vaccination during adolescence-correlates to the prevalence of pancreatic and thyroid autoantibodies. Pediatrics 1999; 104: el2
39. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination and type 1 diabetes. N Engl J Med 2004;350:1398-404 (Pubitemid 38419993)
40. Allen HF, Klingensmith GJ, Jensen P, Simoes E, Hayward A, Chase HP. Effect of Bacillus Calmette-Guerin vaccination on newonset type 1 diabetes. A randomized clinical study. Diabetes Care 1999;22:1703-7 (Pubitemid 29458397)
41. EURODIAB Substudy 2 Study Group. [No authors listed] Infections and vaccinations as risk factors for childhood type I (insulindependent) diabetes mellitus: A multicentre case-control investigation. Diabetologia 2000; 43: 47-53
42. Hyöty H, Hiltunen M, Knip M, Laakkonen M, Vähäsalo P, Karjalainen J et al. A prospective study of the role of Coxsackie B and other enterovirus infections in the pathogenesis of IDDM. childhood diabetes in Finland (DiMe) study group. Diabetes 1995; 44: 6527
43. Yoon JW, Austin M, Onodera T, Notkins AL. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 1979;300:1173-9. (Pubitemid 9191515)
44. Graham KL, Sanders N, Tan Y, Allison J, Kay TW, Coulson BS. Rotavirus infection accelerates type 1 diabetes in mice with established insulitis. J Virol 2008;82:6139-49. (Pubitemid 351875096)
45. Jaeckel E, Manns M, von Herrath M: Viruses and diabetes. Ann N Y Acad Sci. 2002;958:7-25. (Pubitemid 34592201)
46. Vaarala O. The role of the gut in beta-cell autoimmunity and type 1 diabetes: A hypothesis. Pediatr Diabetes 2000; 1: 217-25.
47. Virtanen SM, Knip M. Nutritional risk predictors of beta cell autoimmunity and type 1 diabetes at a young age. Am J Clin Nutr 2003;78:1053-67. (Pubitemid 40003749)
48. Vaarala O. Is it dietary insulin? Ann N Y Acad Sci 2006; 1079: 350-9.
49. Benno Y, Mitsuoka T. Development of intestinal microflora in humans and animals. Bififidobacteria Microfl 1986; 5: 13-25.
50. Matsuzaki T, Nagata Y, Kado S, Uchida K, Kato I, Hashimoto S et at. Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. APMIS 1997;105:643-9. (Pubitemid 27380828)
51. Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 2005;48:1565-75. (Pubitemid 41175510)
52. Elias D, Markovits D, Reshef T, van der Zee R, Cohen IR. Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc Natl Acad Sci USA 1990; 87: 1576-80.
53. Elias D, Cohen IR. Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277. Diabetes 1995; 44: 1132-8.
54. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation witha heat-shock protein peptide (DiaPep277): a randomised, doubleblind, phase II trial. Lancet 2001;358:1749-53. (Pubitemid 33152998)
55. Abulafia-Lapid R, Gillis D, Yosef O, Atlan H, Cohen IR T cells and autoantibodies to human HSP70 in type 1 diabetes in children. J Autoimmun 2003;20:313-21. (Pubitemid 36677523)
56. Lazar L, Ofan R, Weintrob N, Avron A, Tamir M, Elias D et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2007;23:286-91 (Pubitemid 46851469)
57. Schloot NC, Meierhoff G, Lengyel C, Vándorfi G, Takács J, Pánczél P et al. Effect of heat shock protein peptide DiaPep277 on betacell function in paediatric and adult patients with recent-onset diabetes mellitus type 1 : two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 2007;23:276-85. (Pubitemid 46851468)
58. Huurman VA, van der Meide PE, Duinkerken G, Willemen S, Cohen IR, Elias D et al. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol 2008;152:488-97. (Pubitemid 351661507)
59. Schloot N et al. Abstract IDS, Victoria 2012.
60. Rax I et al. Abstract ADA 2012.
61. Theodoropoulos DS, Lockey RF. Allergen immunotherapy: guidelines, update, and recommendations of the world health organization. Allergy Asthma Proc 2000; 21: 159-66.
62. Ludvigsson J. Adequate doses of autoantigen administered using the appropriate route may create tolerance and stop autoimmunity. Diabetologia 2009; 52.
63. Martens HGoxe B, Geenen V. The thynmic repertoire of neuroendocrine- related self-antigens: physiological implications in T-cell life and death. Immunol Today 1996; 17: 312-7.
64. Kyewski B, Klein L A central role for central tolerance. Annu Rev Immunol 2006; 24: 571-606.
65. Castermans E, Baron F, Willems E, Schaaf-Lafontaine N, Meuris N, Gothot A et al. Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning. Haematologica 2008;93:240-7. (Pubitemid 351397712)
66. Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 2009; 9: 833-44.
67. Fan Y, Rudert WA, Grupillo M, He J, Sisino G, Trueco M. Thymusspecific deletion of insulin induces autoimmune diabetes. EMBO J 2009; 28: 2812-24.
68. Pozzilli P. The DPT-I trial: a negative result with lessons for future type 1 diabetes prevention. Diabetes Metab Res Rev 2002; 18: 257-9
69. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005;28:1068-76. (Pubitemid 40616615)
70. Every AL, Kramer DR, Mannering SI, Lew AM, Harrison LC. Intranasal vaccination with proinsulin DNA induces regulatory CD4+ T cells that prevent experimental autoimmune diabetes. J Immunol 2006; 176: 4608-15.
71. Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: A double-blind, randomised controlled trial. Lancet 2008; 372: 1746-55.
72. Song HY, Abad MM, Mahoney CP, McEvoy RC. Human insulin B chain but not A chain decreases the rate of diabetes in BB rats. Diabetes Res Clin Pract 1999;46:109-14. (Pubitemid 29509917)
73. Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010; 34: 408-15.
74. Baekkeskov S, Nielsen JH, Marner H, Bilde T, Ludvigsson J, Lernmark A. Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature 1982;298:167-9. (Pubitemid 12087509)
75. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M et al. Identification of the 64K autoantigen in insulindependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347: 151-6.
76. Tian J, Clare-Salzler M, Herschenfeld A, Middleton B, Newman D, Mueller R et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetesprone mice. Nature Medicine 1996; 2: 1348-53.
77. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T cells inhibits ongoing autoimmune diabetes in non-obese diabetic mice. Diabetes 1998;47:894-9. (Pubitemid 28255662)
78. .Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005;19:238-46. (Pubitemid 40910206)
79. Agardh C-D, Lynch K, Palmer M, Link K, Lernmark A. GAD65 vaccination significantly reduces insulin dependence at five years follow-up in a dose escalating study in adult-onset autoimmune diabetes patients. Diabetologia 51 2008;( Suppl.l): S230.
80. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359: 1909-20.
81. Ludvigsson J, Hjorth M, Chéramy M, Axelsson S, Pihl M, Forsander G et al. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: A randomised controlled trial. Diabetologia 2011; 54: 634-40.
82. Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012; 366: 433-42.
83. Chéramy M, Skoglund C, Johansson I, Ludvigsson J, Hampe CS, Casas R. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD(65) enzyme activity and humoral response. Clin Immunol 2010; 137: 31-40.
84. Axelsson S, Chéramy M, Hjorth M, Pihl M, Akerman L, Martinuzzi E et al. Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes. PLoS One 2011; 6: e29008.
85. Hjorth M, Axelsson S, Rydén A, Faresjö M, Ludvigsson J, Casas R. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients. Clin Immunol 2011; 138: 117-26.
86. Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomised double-blind trial. Lancet 2011; 378: 319-27.
87. von Herrath MG, Whitton JL DNA vaccination to treat autoimmune diabetes. Ann Med 2000;32:285-92. (Pubitemid 30488774)
88. Coon B, An LL, Whitton JL, von Herrath MG DNA immunization to prevent autoimmune diabetes. J Clin Invest 1999; 104: 189-94
89. Zhang W, Jin H, Hu Y, Yu Y, Li X, Ding Z et al. Protective response against type 1 diabetes in nonobese diabetic mice after coimmunization with insulin and DNA encoding proinsulin. Hum Gene Ther 2010; 21: 171-8.
90. Bot A, Smith D, Bot S, Hughes A, Wolfe T, Wang L et al. Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J Immunol 2001;167:2950-5. (Pubitemid 32768931)
91. Tisch R, Wang B, Weaver DJ, Liu B, Bui T, Arthos J, Serreze DV. Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J Immunol 2001; 166: 212232.
92. Weaver DJ Jr, Liu B, Tisch R. Plasmid DNAs encoding insulin and glutamic acid decarboxylase 65 have distinct effects on the progression of autoimmune diabetes in nonobese diabetic mice. J Immunol 2001;167:586-92. (Pubitemid 32567827)
93. Jun HS, Chung YH, Han J, Kim A, Yoo SS, Sherwin RS et al. Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase. Diabetologia 2002;45:668-76. (Pubitemid 34810691)
94. Rother KI, Spain LM, Wesley RA, Digon BJ 3rd, Baron A, Chen K et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care 2009; 32: 2251-7.
95. Dungan KM, Buse JB, Ratner RE. Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). Diabetes Metab Res Rev 2009; 25: 558-65.
96. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes; a birth-cohort study. Lancet 2001;358:1500-3. (Pubitemid 33055701)
97. Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008;93:512-7. (Pubitemid 352025770)
98. Walter M, Kaupper T, Adler K, Foersch J, Bonifacio E, Ziegler AG et al. No effect of the la,25-dihydroxyvitamin D3 on β-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 2010; 33: 1443-8.
99. Bizzarri C, Pitocco D, Napoli N, Di Stasio E, Maggi D, Manfrini S et al. and the IMDIAB Group. No protective effect of calcitriol on β-cell function in recent-onset type 1 diabetes. The Imdiab XIII trial. Diabetes Care 2010; 33: 1962-3.
100. Pickersgill LM, Mandrup-Poulsen TR. The anti-interleukin-1 in type 1 diabetes action trial-background and rationale. Diabetes Metab Res Rev 2009; 25: 321-4.